Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of October 26th – November 1st, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view the full article.
Following RWB’s IPO This Summer, the Company Has Executed Flawlessly Closing a Legendary String of Deals Including the Blockbuster High Times and Platinum Vape Deals
Rising cannabis Multi-State Operator (MSO) and new kid on the block Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) has quickly made a name for itself in a very competitive American Marijuana industry alongside big names like Trulieve (CSE: TRUL) (OTCQX: TCNNF), Curaleaf (CSE: CURA) (OTCQX: CURLF), Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2) and Cresco Labs (CSE: CL) (OTCQX: CRLBF).
The Recent Publication of the Potential of N-acetyl-cysteine (NAC) in the Treatment of COVID-191 Serves as Further Validation for Bucillamine
Revive Therapeutics (CSE: RVV) (OTCPK: RVVTF) (FRA: 31R) announced an update on the company’s U.S. FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020.
The Research Will Be Led By Prof. Dr. Gerhard Gründer, the Only confirmed Scientist Developing a Study to Work With Psychedelics in Germany Since the 1970s
The Shares Were Disposed of By an LLC Controlled By GTI Chief Executive Ben Kovler
Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2) confirmed that an undisclosed institutional investor bought 5.5 million subordinated voting shares in the company for $79 million.
Post-Financing Cash Reserves of CAD $50.1m to Enable Continued Advancement of Diverse and Growing Clinical Trial Pipeline of Psychedelics
MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: BGHM) announced that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriter’s over-allotment option. In connection with the offering, the company issued 27,381,500 units at a price of $1.05 for gross proceeds of $28,750,575. Canaccord Genuity Corp. acted as sole book-runner and underwriter in the Offering.
Cue MC Hammer’s Hit “U Can’t Touch This” For Robinhood Investors Who Want to Scoop Up Shares of These Hot Stocks
Sorry, Robinhood investors. There are some stocks that you just can’t buy on the popular trading platform. Here are three fast-growing Pot Stocks that Robinhood investors can’t buy right now but would probably love: Curaleaf (CSE: CURA) (OTCQX: CURLF), Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2), Trulieve (CSE: TRUL) (OTCQX: TCNNF).
Results Confirm That Field Trip’s Novel Psychedelic Molecule is Similar in Potency to Psilocybin But With Shorter Duration of Psychoactivity Making it a Potentially Preferable Option for Psychedelic Therapies
Field Trip Health (CSE: FTRP) (OTC: FTRPF), the leader in the development and delivery of Psychedelic therapies, provided an update on its in-vivo and in-vitro studies on FT-104, its lead drug candidate.
Stifel GMP Analyst Andrew Partheniou Says U.S. Cannabis Markets are Looking Better Than Previously Expected, Notably in Key Markets in Illinois, Pennsylvania, Massachusetts and California
That’s good news for at least three cannabis stocks with exposure to those states, says Partheniou, who on Monday delivered a report on the state of the industry and highlighted three stocks to outperform: TerrAscend (CSE: TER) (OTCQX: TRSSF), Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2) and Cresco Labs (CSE: CL) (OTCQX: CRLBF).
Psychedelic Drugs Are Losing Their Negative Stigma, Paving the Way for Major Gains in Psychedelic Stocks
Today, psychedelics — like LSD, MDMA and “Magic Mushrooms” — are on the cusp of a Shroom Boom, wherein psychedelic-inspired treatments will go from taboo to the mainstream. Against that backdrop, Psychedelic Stocks will roar higher. With that in mind, some of the best psychedelic stocks to buy for potentially huge gains are: MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: BGHM), Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496), Revive Therapeutics (CSE: RVV) (OTCPK: RVVTF) (FRA: 31R).
Cannabis Can Finally Roll Up Some Profits if November Brings a Blue Wave to Washington
Last month, Sen. Kamala Harris, the running mate of former Vice President Joe Biden, announced in a virtual town hall, “we will decriminalize the use of marijuana…” But will that be enough to save embattled Marijuana Stocks? Here are seven to buy now for a post-election bump: Curaleaf (CSE: CURA) (OTCQX: CURLF), Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1), Cronos Group (TSX: CRON) (NASDAQ: CRON) (FRA: 7CI), Tilray (NASDAQ: TLRY) (FRA: 2HQ), Innovative Industrial Properties (NYSE: IIPR), Charlottes Web (TSX: CWEB) (OTCQX: CWBHF) and Turning Point Brands (NYSE: TPB).